A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Clinical trial NCT07470853 · RECRUITING

Trial details

NCT number: NCT07470853
Sponsor: Whitehawk Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

PROC Platinum Resistant Ovarian Cancer Endometrial Cancer

Start date: 2026-03-15
Primary completion: 2028-02-01
Enrollment: 265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.